BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Sep 20, 2012
 |  BC Extra  |  Company News

Dyax licenses preclinical cancer compound to Kadmon

Dyax Corp. (NASDAQ:DYAX) granted Kadmon Corp. LLC (New York, N.Y.) exclusive, worldwide rights to develop and commercialize preclinical cancer compound DX-2400. Dyax will...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >